← Back to Clinical Trials
Recruiting NCT06943469

NCT06943469 Effect of Partially Hydrolyzed Formula With Synbiotics on Skin Barrier Function

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06943469
Status Recruiting
Phase
Sponsor Société des Produits Nestlé (SPN)
Condition Atopic Dermatitis (AD)
Study Type INTERVENTIONAL
Enrollment 400 participants
Start Date 2025-04-10
Primary Completion 2027-10

Eligibility & Interventions

Sex All sexes
Min Age 1 Day
Max Age 14 Days
Study Type INTERVENTIONAL
Interventions
Test formulaControl formula

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 400 participants in total. It began in 2025-04-10 with a primary completion date of 2027-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The main purpose of this study is to assess the efficacy of a partially hydrolyzed formula with synbiotics in halting one of the first steps of the allergic march (atopic dermatitis) in infants at risk of allergy. Other efficacy and safety parameters will be assessed as well.

Eligibility Criteria

Inclusion Criteria: 1. Written informed consent has been obtained from at least one parent or legally acceptable representative (LAR), if applicable 2. Infant gestational age ≥ 37 completed weeks 3. Infant birth weight of ≥ 2.5 kg and ≤ 4.5 kg 4. Infant postnatal age ≤ 14 days (date of birth = day 0) at enrollment 5. Infant from singleton birth or infant from multiple births may if all birth siblings are enrolled. 6. At least one biological parent or sibling has (or had) a medically diagnosed history of allergy, based on response to a simple screening questionnaire 7. a. For the breastfed reference group only: infant is exclusively breastfed since birth with no intake of formula, and their parent(s) have the intention to continue exclusive breastfeeding until at least 4 months of age. or b. For the randomized formula-fed groups only: infant is exclusively or predominantly formula-fed in the 24 hours prior to enrollment, with formula feeding representing at least 75% of total daily feeds. The decision to introduce formula feeding was independently made by the parents before enrollment. 8. Parents/LAR must be able to provide evidence of parental authority and identity. 9. Infant's parent(s)/LAR must understand the informed consent form and other study documents and are willing and able to fulfill the requirements of the study protocol. Exclusion Criteria: 1. Infectious, metabolic, congenital, genetic, gastrointestinal illness or any other condition (e.g., gastrointestinal surgery) that could impact oral feeding, growth or study outcomes. 2. Infants with special dietary needs other than standard infant formula (e.g., extensively hydrolyzed formula, amino acid formula, special formula for metabolic diseases) or requiring tube feeding. 3. Infant has already been diagnosed with allergy by a physician, including AD and/or cow's milk allergy. 4. Infant is currently participating or has previously participated in another clinical trial prior to enrollment. 5. Infant's parents or LARs have not reached legal age of majority (18 years).

Contact & Investigator

Central Contact

Amelie Goyer, PhD

✉ Amelie.Goyer1@rd.nestle.com

📞 +41217858939

Frequently Asked Questions

Who can join the NCT06943469 clinical trial?

This trial is open to participants of all sexes, aged 1 Day or older, up to 14 Days, studying Atopic Dermatitis (AD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06943469 currently recruiting?

Yes, NCT06943469 is actively recruiting participants. Contact the research team at Amelie.Goyer1@rd.nestle.com for enrollment information.

Where is the NCT06943469 trial being conducted?

This trial is being conducted at Bruges, Belgium, Brussels, Belgium, Namur, Belgium, Amiens, France and 11 additional locations.

Who is sponsoring the NCT06943469 clinical trial?

NCT06943469 is sponsored by Société des Produits Nestlé (SPN). The trial plans to enroll 400 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology